Filing Details
- Accession Number:
- 0001209191-20-001209
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-01-03 17:17:09
- Reporting Period:
- 2019-12-31
- Accepted Time:
- 2020-01-03 17:17:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178879 | Amicus Therapeutics Inc. | FOLD | Pharmaceutical Preparations (2834) | 200422823 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1400971 | L Bradley Campbell | C/O Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury NJ 08512 | Chief Operating Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2019-12-31 | 15,556 | $9.74 | 253,987 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2020-01-02 | 119,780 | $0.00 | 373,767 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2020-01-02 | 14,627 | $9.56 | 359,140 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-01-02 | 7,500 | $5.96 | 366,640 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-01-02 | 7,500 | $9.61 | 359,140 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (right to buy) | Acquisiton | 2020-01-02 | 188,257 | $0.00 | 188,257 | $9.55 |
| Common Stock | Stock Options (right to buy) | Disposition | 2020-01-02 | 7,500 | $0.00 | 7,500 | $5.96 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 188,257 | 2030-01-02 | No | 4 | A | Direct | |
| 22,500 | 2021-01-19 | No | 4 | M | Direct |
Footnotes
- Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock.
- The Restricted Stock Units will vest in four equal annual installments beginning on January 2, 2021.
- The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.51 to $9.61. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.50 to $9.72. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on the first anniversary of the grant date. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments beginning on the first month thereafter.
- All of the options were fully vested and exercisable as of January 2, 2020.
Billionaire Hedge Funds
